Royalty Pharma plc
RPRX
$35.42
$0.270.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.02% | 1.13% | -3.86% | -2.51% | -5.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.02% | 1.13% | -3.86% | -2.51% | -5.24% |
| Cost of Revenue | -139.60% | -97.88% | 30.64% | -48.00% | 2.33% |
| Gross Profit | 117.56% | 84.82% | -14.65% | 28.72% | -10.56% |
| SG&A Expenses | 115.19% | 30.68% | -5.24% | -13.47% | -11.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -64.80% | -72.02% | 12.61% | -44.95% | -2.35% |
| Operating Income | 93.25% | 102.30% | -13.38% | 52.49% | -8.83% |
| Income Before Tax | 61.67% | 49.03% | -21.72% | 360.18% | 118.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 61.67% | 49.03% | -21.72% | 360.18% | 118.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -80.64% | -74.28% | 16.53% | -202.53% | -65.17% |
| Net Income | 51.61% | 36.76% | -24.31% | 520.96% | 164.07% |
| EBIT | 93.25% | 102.30% | -13.38% | 52.49% | -8.83% |
| EBITDA | -70.61% | -- | -- | -39.58% | -27.35% |
| EPS Basic | 45.22% | 31.18% | -28.90% | 540.84% | 167.31% |
| Normalized Basic EPS | 193.57% | 337.54% | -26.68% | -30.33% | -68.48% |
| EPS Diluted | 45.14% | 31.17% | -28.88% | 6,510.78% | 1,107.22% |
| Normalized Diluted EPS | 210.79% | 366.23% | -18.61% | -40.86% | -73.27% |
| Average Basic Shares Outstanding | 5.66% | 7.23% | 8.15% | 0.36% | 0.93% |
| Average Diluted Shares Outstanding | -2.96% | -1.88% | -1.48% | 5.68% | 5.76% |
| Dividend Per Share | 4.88% | 4.94% | 5.00% | 5.06% | 5.13% |
| Payout Ratio | -0.33% | -0.24% | 0.39% | -0.83% | -0.60% |